Boston, MA, July 14, 2016 --(PR.com
)-- TJ Cradick, Head of Genome Editing at CRISPR Therapeutics, will give a presentation on, “Therapeutic Gene Editing with CRISPR/CAS9” at GTCbio’s 3rd Cell & Gene Therapy conference to be held on September 12-13, 2016 in Boston, MA.
CRISPR-Cas9 systems are programmable nucleases that can be designed to precisely edit the genome to correct disease-causing mutations. CRISPR/Cas systems have enabled a wide range of editing methods in humans and also have enabled genome editing in a long list of plant and animal species. CRISPR/Cas systems are being optimized to drive gene editing. Bioinformatics and design strategies are used to improve and ensure specificity. TJ Cradick will also discuss the use of new CRISPR ortholog systems.
Treatment of disease using cell and gene therapy is now a reality. With emerging technologies and new clinical trials being developed and launched at a growing rate, this meeting will discuss the evolving regulatory challenges and pre-clinical requirements, emerging technologies, the development and applications of cell and gene therapy, as well as business models and commercial milestones. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues and gain fresh perspective on the various research.
This conference is also part of their larger Modern Drug Discovery & Development Summit, which consists of three additional co-located conferences:
3rd Cell & Gene Therapy
11th Drug Design & Medicinal Chemistry
7th Non-Coding RNA & RNAi Therapeutics
4th GPCR in Drug Discovery
For more information, please visit website: www.gtcbio.com/cellandgenetherapy
635 W. Foothill Blvd
Monrovia, CA 91016
Phone: (626) 256-6405
Fax: (626) 466-4433